Beyond Ocular Pressure: Nourishing the Optic Nerve to Prevent Blindness
Glaucoma is not merely a problem of elevated intraocular pressure; it represents a complex neurodegenerative pathology characterized by the progressive loss of retinal ganglion cells (RGCs). While reducing intraocular pressure (IOP) is currently the only approved therapeutic strategy, a significant number of patients continue to lose their sight despite reaching pressure targets. This evidence suggests a critical need to identify complementary mechanisms of action that can offer true neuroprotection.
A recent study published in the prestigious journal Cell Reports Medicine (Tribble et al., 2025) has shed new light on the pathophysiology of the disease, identifying the malfunction of one-carbon metabolism as a determining factor in the vulnerability of visual neurons. The research suggests that a targeted intervention on this metabolic pathway, through the use of vitamin cofactors, can halt the degenerative process.
Homocysteine: A Biomarker of Local Distress
For years, the observation of elevated homocysteine levels in the blood and aqueous humor of glaucoma patients has fueled debate over the causal nature of this amino acid. However, the application of the Mendelian Randomization technique on UK Biobank data has demonstrated that a genetic propensity for higher systemic levels of homocysteine does not directly correlate with the risk of glaucoma or the thickness of retinal nerve fibers.
These data indicate that homocysteine is a pathogenic marker, not a primary cause: its elevation in the retina reflects a local metabolic dysfunction rather than a systemic risk factor. Essentially, the accumulation of homocysteine signals an inefficient “metabolic engine” within the ocular tissue, unable to sustain normal homeostatic functions.
One-Carbon Metabolism: The Pillar of Cellular Repair
The core of the discovery lies in the early and sustained dysregulation of genes involved in one-carbon metabolism. This complex biochemical system is essential for DNA methylation, nucleotide synthesis, and the production of glutathione, which is fundamental for defense against oxidative stress. Transcriptomic analyses conducted on animal models and retinal organoids derived from patient stem cells (iPSCs) show that these alterations precede detectable cell death.
The research highlighted how the loss of efficiency of key enzymes (such as Mtr and Cbs) and the reduced transport capacity of nutrients compromise the resilience of retinal neurons. In this context, the functional deficiency of specific cofactors acts as a catalyst for neurodegeneration.
Therapeutic Synergy: B Vitamins and Choline
The research team tested an oral supplementation protocol consisting of a cocktail of vitamins B6, B9 (folic acid), B12, and choline. The results obtained from experimental models indicate a high-profile therapeutic potential:
- Structural Neuroprotection: Supplementation prevented the loss of retinal ganglion cells, maintaining the integrity of cell bodies even under conditions of chronic ocular hypertension.
- Functional Preservation: Electrophysiological tests (pSTR) confirmed the maintenance of the neurons’ functional response, avoiding the visual decline typical of the disease.
- Pressure Independence: The protective effect was achieved without altering intraocular pressure levels, demonstrating a direct action on neuronal resilience.
- Efficacy Against Toxicity: The treatment proved capable of counteracting degeneration induced by supraphysiological concentrations of homocysteine.
Clinical Perspectives and Systemic Management
Although current epidemiological data require further investigation to establish precise dosages for humans, molecular biology is clear: the one-carbon pathway is a concrete therapeutic target. The availability of these nutrients and their known clinical safety facilitate a potential rapid translation toward new support protocols for patients.
Moving beyond the purely mechanistic approach of ocular pressure means embracing a vision where the health of the optic nerve depends on the biochemical balance of its microenvironment. The integration of these metabolic cofactors does not serve as an alternative to pressure-lowering drugs, but as a synergistic strategy aimed at fortifying nerve tissue against the progression of the pathology, redefining the standards of care in glaucoma.
If your company wishes to create or manufacture a product based on B vitamins and choline for ocular health:
Source: Tribble, J.R., et al. (2025). Dysfunctional one-carbon metabolism identifies vitamins B6, B9, B12, and choline as neuroprotective in glaucoma. Cell Reports Medicine, 6, 102127.
